Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Hum Mutat. 2020 Dec 31;42(2):200–212. doi: 10.1002/humu.24154

Table 2:

Prevelance of BRCA2 VUS Identified in Malaysia and Singapore

Variant No. of carriers (Case) No. of carriers (Control) 1000g_EAS_AF 1000g_EUR_AF gnomAD_AF_Overall gnomAD_ EAS_AF gnomAD_ SAS_AF gnomAD_ NFE_AF sub-pop/general pop Crude odds ratio p-value
c.1600G>A (E534K) 2 1 1.00E-03 NA 2.05E-05 2.92E-04 NA NA 14.23 (EAS) 2.02 0.57
c.3782C>G (S1261C) 1 1 NA NA NA NA NA NA NA 1.01 0.99
c.6322C>T (R2108C) 119 120 3.00E-03 2.00E-03 5.93E-04 6.47E-03 6.83E-05 2.09E-04 10.91 (EAS) 1.00 0.98
c.6929C>A (T2310N) 4 4 NA NA 3.26E-05 NA 1.96E-04 NA 6.02 (SAS) 1.01 0.99
c.8356G>A (A2786T) 10 11 NA NA 6.09e-05 8.12E-04 3.27E-05 NA 13.32 (EAS) 0.99 0.85
c.8393C>T (P2798L) 1 0 NA NA NA NA NA NA NA 3.03 0.50
c.9104A>G (Y3035C) 5 4 NA NA 2.05E-05 2.34E-04 NA 9.07E-06 11.43 (EAS) 1.26 0.73
c.9104A>T (Y3035F) 0 0 NA NA NA NA NA NA NA NA NA
c.9104A>C (Y3035S) 0 0 NA NA 4.99E-05 NA NA 1.02E-04 2.04 (NFE) NA NA
c.9106C>G (Q3036E) 4 2 1.00E-03 0 3.93E-05 5.27E-04 NA NA 13.43 (EAS) 2.02 0.42
c.9344A>G (K3115R) 1 1 NA NA 4.47e-05 NA 2.00E-04 NA 4.47 (SAS) 1.01 0.99
c.9538C>T (L3180F) 2 2 1.00E-03 NA 4.06E-05 5.22E-04 NA NA 12.85 (EAS) 1.01 0.99
c.9907A>T S3303C) 1 0 NA NA NA NA NA NA NA 3.03 0.50
c.68–7T>A (IVS2–7T>A) 5 1 NA NA 2.84E-03 2.02E-04 1.90E-03 2.46E-03 NA* 5.06 0.14
c.632–10dupT (IVS710insT) 1 0 NA NA NA NA NA NA NA 3.03 0.50
c.8954-5_89542delAACA (IVS225delAACA) 24 26 NA NA 1.06E-04 1.51E-03 NA NA 14.14 (EAS) 0.93 0.81

1000g_EAS and 1000g_EUR: Allelic frequency in East Asians and Europeans respectively in 1000 genome database; gnomAD_Overall, gnomAD_EAS, gnomAD_SAS, and gnomAD_NFE: Allelic frequency overall, and in East Asians, South Asians and Non-Finnish Europeans respectively in the gnomAD database; Enrichment in Asians: enrichment of variant in either East Asian (EAS) or South Asian (SAS) population compared to the allelic frequency in gnomAD overall

*

indicates MAF»0.3% in general population; Crude odds ratio were calculated using total breast cases (n=7840) vs controls (n=7928); NA: not applicable.